Business
Neurophet Showcases Full-Cycle Brain Imaging Analysis Solutions for Alzheimer's disease Including 'Neurophet AQUA AD' at AAIC 2025
Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on the 31st that it participated in the Alzheimer's Association International Conference (AAIC 2025), showcasing its flagship brain imaging analysis AI solutions.
About this update from Neurophet, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Showcased brain imaging analysis products such as Neurophet AQUA AD, capable of monitoring side effects of Alzheimer's disease treatments","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"Engaged in partnering with global big pharma and neurology KOLs, seeking global development collaborations for key products","length":123,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":264,"olType":false},{"type":"text","content":"SEOUL, South Korea, July 31, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on the 31st that it participated in the Alzheimer's Association International Conference (AAIC 2025), showcasing its flagship brain imaging analysis AI solutions.","length":381,"tagName":"p"},{"type":"image","alt":"Jake Junkil Been, Co-CEO of Neurophet, delivering a presentation at AAIC 2025","displaySize":"","headline":null,"caption":"Jake Junkil Been, Co-CEO of Neurophet, delivering a presentation at AAIC 2025","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":300,"url":"https://media.zenfs.com/en/prnewswire.com/fa5029c6d905517ea3485748064ac08f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5EWZwucTI_QLD_xLaTZ.Ew--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTUyOTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/fa5029c6d905517ea3485748064ac08f","width":400,"height":300}},"href":"https://mma.prnewswire.com/media/2740766/Jake_Junkil_Been__Co_CEO_of_Neurophet__delivering_a_presentation_at_AAIC_2025.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"At the conference, Jake Junkil Been, Co-CEO of Neurophet, delivered a presentation titled "Neurophet in the Era of Paradigm Shift in Alzheimer's Disease: The Journey to IPO and Beyond," introducing the company's vision and roadmap.","length":249,"tagName":"p"},{"type":"text","content":"During the event, Neurophet introduced Neurophet AQUA AD, neuroimaging analysis software designed to monitor the prescription, treatment effects, and side effects of amyloid-targeted therapeutics for Alzheimer's disease. Neurophet AQUA AD quantitatively analyzes MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) scans, ...